Outlook Therapeutics, Inc. Banner Image

Outlook Therapeutics, Inc.

  • Ticker OTLK
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Outlook Therapeutics, Inc. Logo Image
  • 11-50 Employees
  • Based in Cranbury, New Jersey
Outlook Therapeutics is a late clinical-stage biopharmaceutical company working to develop ONS-5010 / LYTENAVA™ (bevacizumab-vikg) as the first FDA-approved ophthalmic formulation of bevacizumab-vikg for use in retinal indications, including wet AMD, DME and BRVO. If ONS-5010 is approved, Outlook Therapeutics expects to commercialize it as the first and only FDA-approved ophthalmic formulationMore of bevacizumab-vikg for use in treating retinal diseases in the United States, United Kingdom, Europe, Japan and other markets. Outlook Therapeutics expects to file ONS-5010 with the U.S. FDA as a new BLA under the PHSA 351(a) regulatory pathway.
Outlook Therapeutics, Inc.

Most Recent Annual Report

Outlook Therapeutics, Inc.
MOST RECENT 2021 Annual Report and Form 10K

Older/Archived Annual Reports